trending Market Intelligence /marketintelligence/en/news-insights/trending/F3xNhKDyQRgFFT8LgLBjHA2 content esgSubNav
In This List

Nexstim gets positive US FDA response on proposed stroke trial plan

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Nexstim gets positive US FDA response on proposed stroke trial plan

Nexstim PLC said the U.S. FDA provided a positive response to its proposed limited size trial protocol for its NBT stroke rehabilitation system.

Data from the new trial will be combined with data from the previous phase 3 trial in accordance with the FDA recommendation. The FDA also stated that Nexstim's new sham coil design is appropriate for the new trial.

The response provides Nexstim the possibility to start the new 60-patient trial in the first quarter of 2017.

Nexstim expects the trial to be completed in the first quarter of 2018 and expects to receive de novo 510(k) clearance from U.S. FDA in the fourth quarter of 2018. This clearance will allow Nexstim to start marketing and selling its stroke rehabilitation system in the U.S.